Dublin medtech Vertigenius to accelerate its US rollout of remote monitoring device for vertigo as insurers open new reimbursement pathways.
Irish medtech Vertigenius has raised €2.55m in a new funding round that will support its expansion into the United States on the heels of early commercial traction after its US market launch late last year.
The investment – which follows a €2.1m fundraising round in 2024 – was led by Atlantic Bridge and supported by Enterprise Ireland, MedTech Syndicate, IRRUS Investments, Xcendra Ventures, Ascentifi and others.
“For the first time, clinicians have a direct view of at-home patient treatment”
With FDA registration complete, Vertigenius launched in the US market in October 2025. Already, 20 clinics across 11 US states are now using the Vertigenius medical device and 3,000 patients have been treated.
How Vertigenius works
Mark Barry, CEO, Vertigenius; Dr Dara Meldrum, Founder and Chief Scientific Officer, Vertigenius; and Conor O’Sullivan, Investment Director, Atlantic Bridge
Vertigo is a common, highly treatable, but often debilitating condition affecting 390 million people worldwide. Causes include concussion, traumatic brain injury, and the natural degradation of the balance system with age.
While most patients recover through referral to a vestibular therapist and home-based rehabilitation exercises, there has been no means of remotely monitoring patient progress, until now.
Vertigenius transforms the delivery of care for vertigo patients by enabling remote monitoring for the first time. The wearable head sensor medical device allows clinicians to track patients’ at-home treatment remotely, monitor progress and adjust prescribed treatment accordingly.
By accelerating clinician workflows and reducing the number of clinic visits required, Vertigenius eases critically long waiting lists to see vestibular therapists, and supports overstretched teams. Additionally, in the US, clinics can access additional insurance reimbursement1 for remote monitoring of patients, opening up previously unavailable income streams.
The US represents a lucrative market opportunity for Vertigenius, with an addressable market of over €3bn and a network of more than 5,000 vestibular clinics. Expansion there is therefore a key focus for this latest funding round.
“For the first time, clinicians have a direct view of at-home patient treatment,” said Vertigenius CEO Mark Barry.
“By transforming real-time data into clinically relevant insights, providers can now proactively tailor treatments and significantly elevate the standard of patient care that they are providing.
“This investment marks an exciting new chapter for Vertigenius as we move into the world’s largest market for vestibular care. The early traction we have seen in the US validates both the clinical value of our platform and the commercial opportunity.”
Over the next five years, Vertigenius anticipates expanding further in Europe and entering other markets including Asia Pacific to transform the treatment of vertigo globally.
“Vertigenius is addressing a significant gap in vestibular care in a multi-billion dollar market,” said Conor O’Sullivan, investment director, Atlantic Bridge.
“The team has built a unique platform that is significantly enhancing the delivery of vestibular care by supporting clinicians and patients between visits, and we are excited to back their US expansion.”
Top image: Dr Dara Meldrum, founder and Chief Scientific Officer, Vertigenius, and Conor O’Sullivan, Investment Director, Atlantic Bridge
-
Bank of Ireland is welcoming new customers every day – funding investments, working capital and expansions across multiple sectors. To learn more, click here
-
For support in challenging times, click here
-
Listen to the ThinkBusiness Podcast for business insights and inspiration. All episodes are here. You can also listen to the Podcast on:
-
Spotify
-
SoundCloud
-
Apple
